Skip to content

SG&A at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.62B+2.1%
Incyte logo
IncyteINCY
$328.09M+0.7%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$44.92M+48.6%
Celcuity logo
CelcuityCELC
$17.44M+174%
Exelixis logo
ExelixisEXEL
$139.6M+1.8%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$352.7M-31.4%

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$888.51M-8.6%
Enterprise value$973.78M-6.2%
P/S4.7×-174×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's SG&A?
Geron (GERN) reported SG&A of $35.43M in Q1 2026.
How has Geron's SG&A changed year-over-year?
Geron's SG&A decreased by 11.5% year-over-year, from $40.02M to $35.43M.
What is the long-term trend for Geron's SG&A?
Over 3 years (2022 to 2025), Geron's SG&A has grown at a 54.0% compound annual growth rate (CAGR), from $43.63M to $159.26M.
What does SG&A mean?
Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.